BEAM (Beam Therapeutics) Projected Sales Volume

Graphic logo of Beam Therapeutics (BEAM)

The target sales volume for Beam Therapeutics Inc. (BEAM) demonstrates growth potential, bolstered by a strategic alliance with Pfizer to develop precision DNA modification methods. This trend is supported by a broad spectrum of developments—ranging from hematology to oncology—while the 0.15 level indicates the parameter's current state. The company's success is based on attracting leading geneticists motivated by an innovative culture and a generous equity package.

Company Expected Revenue: Beam Tx (BEAM) for 07/04/2022 - 11/17/2026

Analytical breakdowns for Beam Therapeutics Inc.

- stock value and consensus price forecast:
Summary company analysis:Beam Therapeutics Inc
Product sample of Beam Tx

For Beam Therapeutics Inc. (BEAM), business viability depends on successfully overcoming regulatory hurdles and completing clinical trials. This metric quantifies market expectations for future revenue, reflecting the capitalization of commercial prospects for genome editing, which allows investors to identify the gap between management optimism and the actual market valuation of the asset through the company's projected sales volumes.

Main competitors

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|SRPT (Sarepta Therapeutics) - Projected Sales Volume|Company Expected Sales Volume Twist Bioscience Corp TWST|Projected Sales Volume TXG|Projected Sales Volume intelliatx.com (NTLA)|Stoke Therapeutics - Company Future Sales Volume|BioLife Solutions Inc (BLFS) - Company Expected Sales Volume|wavelifesciences.com - Projected Sales Volume|Maze Therapeutics Corp (MAZE) - Company Future Sales Volume|SION: Projected Sales Volume|Company Revenue Forecast PRME|Company Projected Revenue Taysha Gene Therapies|Company Revenue Forecast QURE (uniQure)|Company Projected Revenue MeiraGTx (MGTX)|REGENXBIO Corp - Company Revenue Forecast|Company Projected Revenue Solid Biosciences SLDB|OCGN - Company Future Sales Volume|pacb.com - Projected Sales Volume|Benitec (BNTC) - Company Future Sales Volume|DSGN: Projected Sales Volume|RCKT - Company Future Sales|FDMT: Company Future Sales|Company Revenue Forecast LXEO (lexeotx.com)|Company Projected Revenue Korro Bio Inc. (KRRO)|Company Projected Revenue Volume EDIT|Projected Sales Volume SLN (Silence Therapeutics PLC)|Company Future Revenue PRQR|CDXS - Company Projected Revenue|SGMO (Sangamo Therapeutics) - Company Revenue Forecast|NAUT: Projected Sales Volume|Company Revenue Forecast MGX|DTIL (precisionbiosciences.com) - Projected Sales Volume|Company Revenue Forecast GBIO (Generation Bio Co.)|Company Projected Revenue Boundless Bio (BOLD)|Exicure - Company Revenue Forecast|Projected Sales Volume IMNN (imunon.com)|Company Future Sales Phio Pharmaceuticals (PHIO)|MBIO: Company Future Sales Volume|Company Future Revenue RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Company Projected Revenue|APDN - Company Future Sales|Company Future Sales Volume BLUE|Projected Sales Volume immunoprecise.com|Projected Sales Volume OMGA|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume